GovWire

Decision: Regulatory approval of Pfizer/BioNTech bivalent Original/Omicron booster vaccines

Medicines Healthcare Products Regulatory Agency

September 12
07:50 2023

31 August 2023 - Summary of Product Characteristics - Pfizer/BioNTech bivalent vaccine - BA.4-5 (1.5/1.5 micrograms)/dose for age 6 months to 4 years

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

31 August 2023 - Patient Information Leaflet - Pfizer/BioNTech bivalent vaccine - BA.4-5 (1.5/1.5 micrograms)/dose for age 6 months to 4 years

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Last updated 08/2023 - Summary of Product Characteristics - Pfizer/BioNTech bivalent vaccine - Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose for age 12+

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Last updated 08/2023 - Summary of Product Characteristics - Pfizer/BioNTech bivalent vaccine - Comirnaty Original/Omicron BA.4-5 (5/5 micrograms)/dose for ages 5-11 years

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Related Articles

Comments

  1. We don't have any comments for this article yet. Why not join in and start a discussion.

Write a Comment

Your name:
Your email:
Comments:

Post my comment

Recent Comments

Follow Us on Twitter

Share This


Enjoyed this? Why not share it with others if you've found it useful by using one of the tools below: